Klaus Gubernator & Hans-Joachim Böhm 
Structure-based Ligand Design 

Most drugs bind to a clearly defined macromolecular target that is complementary in terms of structure and chemistry. This observation is the basic paradigm of structure-based ligand design. Although this method first emerged in the 1980s, it has already become a powerful tool for pharmaceutical research. Much has been learned, however, since the first attempts to discover drugs on the basis of available biochemical and structural data. Nowadays, structure-based ligand design is an established method for creating drugs with new structural features, for modifying binding activities and pharmacokinetic properties, and for elucidating binding modes and structure-activity relationships.

This volume presents the underlying principles of the approach and highlights real-life applications such as the discovery of HIV-protease inhibitors. It shows that structure-based ligand design has many advantages over other more traditional approaches to designing new drugs, providing it is employed properly and with a thorough knowledge of the pitfalls to avoid.

The straightforward presentation and extensive list of references to the original literature as well as numerous color figures illustrating structural relationships make this volume an indispensable tool for every scientist working in the area of drug discovery.

Table of Content

Rational Design of Bioactive Molecules
Examples of Active Areas of Structure-Based Design
From Renin to HIV-1 Protease
Zinc Endoproteases: A Structural Superfamily
Structure-Based Design of Potent Beta-Lactamase Inhibitors
Inhibition of Sialidase
Rational Design of Inhibitors of HIV-1 Reverse Transcriptase
New Computational Approaches to Predict Protein-Ligand Interactions
The Future of Structure-Based Design: A Worthy Precept?